Back to Search Start Over

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer

Authors :
Filipe LF. Carvalho
Alexander Zeymo
Jillian Egan
Colleen H. Kelly
Chaoyi Zheng
John H. Lynch
Jonathan Hwang
Lambros Stamatakis
Ross E. Krasnow
Keith J. Kowalczyk
Source :
Investigative and Clinical Urology, Vol 61, Iss 4, Pp 390-396 (2020)
Publication Year :
2020
Publisher :
Korean Urological Association, 2020.

Abstract

Purpose: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is standard of care for muscle-invasive bladder cancer (MIBC). However, NAC is used in less than 20% of patients with MIBC. Our goal is to investigate factors that contribute to underutilization NAC to facilitate more routine incorporation into clinical practice. Materials and Methods: We identified 5,915 patients diagnosed with cT2-T3N0M0 MIBC who underwent RC between 2004 and 2014 from the National Cancer Database. Univariate and multivariable models were created to identify variables associated with NAC utilization. Results: Only 18.8% of patients received NAC during the study period. On univariate analyses, NAC utilization was more likely at academic hospitals, US South and Midwest (p

Details

Language :
English
ISSN :
24660493 and 2466054X
Volume :
61
Issue :
4
Database :
Directory of Open Access Journals
Journal :
Investigative and Clinical Urology
Publication Type :
Academic Journal
Accession number :
edsdoj.173ccf56e344aa9b43dc1f62db1578a
Document Type :
article
Full Text :
https://doi.org/10.4111/icu.2020.61.4.390